"Surveys of patients with SLE and other autoimmune and inflammatory rheumatic diseases have identified vaccine hesitancy in up to 50% of patients, which may be related to concerns about side effects, potential disease flares, or lack of data among patients with SLE.”
Findings demonstrate the utility of machine learning in aiding clinical risk stratification within a complex patient cohort.
Results underline the importance of psychiatric evaluation and treatment in patients with fibromyalgia.
The findings of this study of anti-CD19 directed CAR T cell therapy offers new hope for the most severe and refractory cases.
Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending October 1, 2022.
A long-term, post-authorization safety study of adverse events was performed for patients with PsO and/or PsA exposed to apremilast.
The 3-stage Delphi exercise used the expertise of medical and health care professionals with experience in treating patients with fibromyalgia. Treatment recommendations included exercise, education, cognitive behavioral therapy, mindfulness, and mind-body exercises.
Although the proportion of women treated with biologics continues to grow, data on treatment recommendations among both physicians and female patients of childbearing age remain limited.
Throughout the pandemic, rheumatologists have been concerned that their patients may be at risk of developing more severe forms of the COVID-19 disease as a result of their rheumatic disease or treatment.
“This class of medication provides an alternative therapeutic option for those that have an inadequate response to conventional DMARDs or biologic therapy.”
People with rheumatoid arthritis are at increased risk of osteoporosis. Test your knowledge of how the risk of osteoporosis can be minimized in these patients.
Kim Bennell, PhD, discusses her study “Effectiveness of an Unsupervised Online Yoga Program on Pain and Function in People With Knee Osteoarthritis: A Randomized Clinical Trial.”
Although results are promising, findings should be interpreted with caution, as the study was underpowered and terminated early due to the COVID-19 pandemic.
Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending September 24, 2022.
Bonnie L Bermas, MD, discusses the ways in which the Supreme Court decision to overturn Roe v Wade will change the way rheumatologists are able to care for their patients.
Although results were associative rather than causative, a decrease in BMI may prevent, delay, or slow the structural defects in knee osteoarthritis.
"Dactylitis is considered a core domain of musculoskeletal symptoms in psoriatic arthritis and is important for both patients and physicians when developing treatment strategies.”
The FDA approved risankizumab in June for adult patients with Crohn’s disease, representing the first IL-23 treatment to be approved for this patient population.
Fatigue, a highly multifactorial manifestation of lupus, can be related to disease activity or independent of the disease itself. Investigators determined whether fatigue could be a significant confounder of Physician Global Assessment ratings.
Despite worldwide trend data, incidence trends for dermatomyositis do not show increases among the study population.
"Online interventions have the potential to reach a wide audience, allowing exercise to be undertaken from the comfort and convenience of home and thereby overcoming some of the barriers to exercise reported in the osteoarthritis population.”
Rebecca Shepherd, MD, MBA, FACR, FACP, discusses the American College of Rheumatology's 2022 Rheumatic Disease Report Card in depth, including what can be done to improve scores and the next steps for her team.
CLEC2B, a key gene linked to ferroptosis regulators in psoriatic arthritis, is differentially expressed in a variety of cancers and is associated with immune cell infiltration as well as immune checkpoints.
Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending September 17, 2022.
The guidelines will provide more options for the treatment and prevention of glucocorticoid-induced osteoporosis and will inform rheumatologists about the requirements for anti-resorptive therapy after anabolic agents are discontinued.
Bimekizumab provided maintenance of completely clear skin and health-related quality of life in most patients with moderate-to-severe plaque psoriasis over a 3-year period.
Results were based on the phase 4 MIRROR trial, which analyzed differences in treatment response for concomitant therapy compared with placebo in adults with uncontrolled gout.
The effect of sleep health on disease prevention may have a profound impact on women when it comes to systemic lupus erythematosus (SLE).
For the second annual Interstitial Lung Disease Day, Dr. Briana DiSilvio expands on the background of ILDs and the latest care practices.
The updated guidelines highlight new recommendations for medications, flexibility in drug selection, and sequential therapy.
